Monitoring Drug Safety in the Age of Big Data
Healthcare databases may allow for greater access to real-world medical data, but they can become a risk to patients and healthcare systems if they are not considered carefully, according to a study published in Current Epidemiology Reports.
After Astra, Pfizer Taps Other Immuno-Oncology Markets
With the immuno-oncology field getting more intense, Pfizer continues its struggle to gain a foothold in the field. Following unsuccessful attempts to bid for AstraZeneca, Pfizer has now signed a deal with a Belgian company, iTeos Therapeutics.
How Should E-Cigarettes Be Regulated?
Should e-cigarettes be regulated he same way as cigarettes? Should marketing and sales restrictions be the same? Policy and health experts chime-in.
Making a Case for Biomarkers in Cancer Immunotherapy
Immune response boosters in oncology, approved for melanoma so far, are being evaluated in several different cancer types. While the drugs perform well, there is a definite need to identify responsive patient cohorts.
One For Choosing Wisely in Breast Cancer
A study presented at the San Antonio Breast Cancer Symposium showed that Herceptin may not complement chemotherapy in breast tumors with a high level of immune infiltration.
Healthcare Law Is Not One-Size-Fits-All, and Here’s Why
One criticism of the Affordable Care Act is that it imposes a costly, one-size-fits-all standard, drastically increasing premiums by requiring everyone to buy health insurance that covers the same mandated benefits. This is not so.
Federal Health IT Strategic Plan Outlines 5 Key Goals
The updated federal health information technology strategic plan is an attempt to collect, share, and use interoperable health information to improve care; enhance individual, community, and public health; and advance research.